| 2.83 0.12 (4.43%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.74  |
1-year : | 4.37 |
| Resists | First : | 3.21 |
Second : | 3.74 |
| Pivot price | 2.55 |
|||
| Supports | First : | 2.6 |
Second : | 2.23 |
| MAs | MA(5) : | 2.69 |
MA(20) : | 2.53 |
| MA(100) : | 2.89 |
MA(250) : | 2.87  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 73.5 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 5.38 | Low : | 1.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OKUR ] has closed Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.88 - 2.89 | 2.89 - 2.9 |
| Low: | 2.62 - 2.64 | 2.64 - 2.65 |
| Close: | 2.81 - 2.83 | 2.83 - 2.85 |
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Sun, 01 Mar 2026
OKUR PE Ratio & Valuation, Is OKUR Overvalued - Intellectia AI
Tue, 17 Feb 2026
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Tue, 23 Dec 2025
OnKure Therapeutics CFO Leverone sells $896 in stock - Investing.com
Thu, 06 Nov 2025
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
Tue, 04 Nov 2025
OnKure Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 88.9 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -4.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.6 % |
| Return on Equity (ttm) | -207.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|